Control of chemotherapy-induced diarrhea with the synthetic enkephalin BW942C: A randomized trial with placebo in patients receiving cisplatin

M. G. Kris, R. J. Gralla, R. A. Clark, L. B. Tyson, S. Groshen

Research output: Contribution to journalArticle

19 Scopus citations


Diarrhea commonly occurs following the administration of cisplatin. BW942C, a pentapeptide, is a synthetic enkephalin shown to control castor oil-induced and traveler's diarrhea. To assess the safety and efficacy of BW942C in controlling diarrhea caused by cisplatin, 30 adults with lung cancer who had already experienced diarrhea (three or more loose bowel movements) during the 24-hour period following a prior cisplatin administration were randomized to receive either BW942C or placebo during the next cisplatin course. All patients received a concomitant antiemetic regimen including metoclopramide, dexamethasone, and lorazepam during all courses. Patients administered BW942C experienced less diarrhea (27% v 67%, P = .02). Twenty-seven percent of patients given the pentapeptide had loose bowel movements as opposed to 93% who received placebo (P = .0002). There were no significant differences in the incidence and degree of vomiting and other treatment-related side effects observed between the placebo and treatment groups. We conclude that oral BW942C is more effective than placebo in controlling diarrhea following cisplatin chemotherapy.

Original languageEnglish (US)
Pages (from-to)663-668
Number of pages6
JournalJournal of Clinical Oncology
Issue number4
Publication statusPublished - Jan 1 1988


ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this